Understand the source comparison
Best KLOW Dosage for Healing: Subject-Specific Comparison
Post-infection immune recovery 50–100 mcg 10 days Thymic T-cell differentiation Normalized CD3+/CD4+ counts, reduced infection recurrence Best for immune reconstitution after acute illness. Higher doses offer no additional T-cell benefit Post-surgical healing
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Post-infection immune recovery
- 50–100 mcg
- 10 days
- Thymic T-cell differentiation
- Normalized CD3+/CD4+ counts, reduced infection recurrence
- Best for immune reconstitution after acute illness. Higher doses offer no additional T-cell benefit
- Post-surgical healing
- 100–150 mcg
- 10–14 days
- Reduced systemic IL-6 and TNF-alpha, enhanced fibroblast activity
- 30–40% faster wound closure, reduced surgical site infection
- Optimal for controlled injury with predictable healing timeline
- Chronic non-healing wounds (diabetic ulcers, pressure sores)
- 150–200 mcg
- 20 days
- Sustained anti-inflammatory signaling, normalized angiogenesis
- Measurable wound bed reduction, improved granulation tissue formation
- Requires extended cycle to overcome chronic inflammatory state
- Age-related immune decline (no acute injury)
- 10 days, repeated quarterly
- Thymic hormone supplementation, compensating for age-related involution
- Improved vaccine response, reduced opportunistic infection rate
- Preventive dosing. Matches endogenous thymic output that declines 3% annually after age 25
- Autoimmune flare management
- 50 mcg
- 10 days (use cautiously)
- T-regulatory cell (Treg) expansion
- Reduced autoantibody titers, symptom stabilization
- Lower dose avoids overstimulating effector T-cells. Requires clinical supervision